Assessment  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
CD105 ||| S:14 E:19 ||| NNP
,  ||| S:19 E:21 ||| ,
α-SMA  ||| S:21 E:27 ||| JJ
and  ||| S:27 E:31 ||| CC
VEGF  ||| S:31 E:36 ||| NNP
expression  ||| S:36 E:47 ||| NN
in  ||| S:47 E:50 ||| IN
gastric  ||| S:50 E:58 ||| JJ
carcinomas  ||| S:58 E:69 ||| NN
In  ||| S:69 E:72 ||| IN
this  ||| S:72 E:77 ||| DT
study ||| S:77 E:82 ||| NN
,  ||| S:82 E:84 ||| ,
we  ||| S:84 E:87 ||| PRP
analyzed  ||| S:87 E:96 ||| VBD
the  ||| S:96 E:100 ||| DT
microvessel  ||| S:100 E:112 ||| JJ
density  ||| S:112 E:120 ||| NNS
( ||| S:120 E:121 ||| -LRB-
MVD ||| S:121 E:124 ||| NNP
)  ||| S:124 E:126 ||| -RRB-
for  ||| S:126 E:130 ||| IN
CD105+  ||| S:130 E:137 ||| NNP
and  ||| S:137 E:141 ||| CC
α-SMA+  ||| S:141 E:148 ||| CD
vessels  ||| S:148 E:156 ||| NNS
and  ||| S:156 E:160 ||| CC
the  ||| S:160 E:164 ||| DT
VEGF  ||| S:164 E:169 ||| NNP
immunoexpression  ||| S:169 E:186 ||| NN
in  ||| S:186 E:189 ||| IN
38  ||| S:189 E:192 ||| CD
gastric  ||| S:192 E:200 ||| CD
carcinomas ||| S:200 E:210 ||| NNS
.  ||| S:210 E:212 ||| .
CD105+  ||| S:212 E:219 ||| NNP
MVD  ||| S:219 E:223 ||| NNP
had  ||| S:223 E:227 ||| VBD
superior  ||| S:227 E:236 ||| JJ
values  ||| S:236 E:243 ||| NNS
at  ||| S:243 E:246 ||| IN
the  ||| S:246 E:250 ||| DT
advancing  ||| S:250 E:260 ||| JJ
edge  ||| S:260 E:265 ||| NN
compared  ||| S:265 E:274 ||| VBN
with  ||| S:274 E:279 ||| IN
the  ||| S:279 E:283 ||| DT
intratumoral  ||| S:283 E:296 ||| JJ
area ||| S:296 E:300 ||| NN
,  ||| S:300 E:302 ||| ,
no  ||| S:302 E:305 ||| DT
matter  ||| S:305 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
analyzed  ||| S:319 E:328 ||| JJ
clinico-pathological  ||| S:328 E:349 ||| JJ
parameters ||| S:349 E:359 ||| NNS
,  ||| S:359 E:361 ||| ,
the  ||| S:361 E:365 ||| DT
difference  ||| S:365 E:376 ||| NN
being  ||| S:376 E:382 ||| VBG
significant  ||| S:382 E:394 ||| JJ
only  ||| S:394 E:399 ||| JJ
in  ||| S:399 E:402 ||| IN
intestinal  ||| S:402 E:413 ||| JJ
type ||| S:413 E:417 ||| NN
,  ||| S:417 E:419 ||| ,
moderate  ||| S:419 E:428 ||| JJ
differentiated  ||| S:428 E:443 ||| JJ
carcinomas  ||| S:443 E:454 ||| NN
as  ||| S:454 E:457 ||| IN
well  ||| S:457 E:462 ||| RB
as  ||| S:462 E:465 ||| RB
in  ||| S:465 E:468 ||| IN
T2-T3  ||| S:468 E:474 ||| CD
carcinomas ||| S:474 E:484 ||| NN
,  ||| S:484 E:486 ||| ,
without  ||| S:486 E:494 ||| IN
lymph  ||| S:494 E:500 ||| FW
node  ||| S:500 E:505 ||| FW
metastases  ||| S:505 E:516 ||| FW
( ||| S:516 E:517 ||| -LRB-
p  ||| S:517 E:518 ||| CD
< ||| S:518 E:519 ||| SYM
0.05 ||| S:519 E:523 ||| CD
) ||| S:523 E:524 ||| -RRB-
.  ||| S:524 E:526 ||| .
Intratumoral  ||| S:526 E:539 ||| JJ
expression  ||| S:539 E:550 ||| NN
of  ||| S:550 E:553 ||| IN
CD105+  ||| S:553 E:560 ||| NNP
MVD  ||| S:560 E:564 ||| NNP
indicated  ||| S:564 E:574 ||| VBD
significant  ||| S:574 E:586 ||| JJ
differences  ||| S:586 E:598 ||| NNS
related  ||| S:598 E:606 ||| VBN
to  ||| S:606 E:609 ||| TO
histological  ||| S:609 E:622 ||| VB
type  ||| S:622 E:627 ||| NN
( ||| S:627 E:628 ||| -LRB-
p=0.006 ||| S:628 E:635 ||| NNP
) ||| S:635 E:636 ||| -RRB-
,  ||| S:636 E:638 ||| ,
depth  ||| S:638 E:644 ||| NN
of  ||| S:644 E:647 ||| IN
invasion  ||| S:647 E:656 ||| NN
( ||| S:656 E:657 ||| -LRB-
p=0.027 ||| S:657 E:664 ||| NNP
)  ||| S:664 E:666 ||| -RRB-
and  ||| S:666 E:670 ||| CC
lymph  ||| S:670 E:676 ||| FW
node  ||| S:676 E:681 ||| FW
metastases  ||| S:681 E:692 ||| FW
( ||| S:692 E:693 ||| -LRB-
p=0.009 ||| S:693 E:700 ||| NNP
) ||| S:700 E:701 ||| -RRB-
,  ||| S:701 E:703 ||| ,
but  ||| S:703 E:707 ||| CC
without  ||| S:707 E:715 ||| IN
statistical  ||| S:715 E:727 ||| JJ
association  ||| S:727 E:739 ||| NN
in  ||| S:739 E:742 ||| IN
case  ||| S:742 E:747 ||| NN
of  ||| S:747 E:750 ||| IN
the  ||| S:750 E:754 ||| DT
advancing  ||| S:754 E:764 ||| JJ
edge  ||| S:764 E:769 ||| NN
or  ||| S:769 E:772 ||| CC
metastases ||| S:772 E:782 ||| NN
.  ||| S:782 E:784 ||| .
The  ||| S:784 E:788 ||| DT
assesses  ||| S:788 E:797 ||| NN
of  ||| S:797 E:800 ||| IN
α-SMA+  ||| S:800 E:807 ||| NNP
MVD  ||| S:807 E:811 ||| NNP
indicated  ||| S:811 E:821 ||| VBD
no  ||| S:821 E:824 ||| DT
differences  ||| S:824 E:836 ||| NNS
between  ||| S:836 E:844 ||| IN
intratumoral  ||| S:844 E:857 ||| NN
and  ||| S:857 E:861 ||| CC
advancing  ||| S:861 E:871 ||| VBG
edge  ||| S:871 E:876 ||| NN
areas ||| S:876 E:881 ||| NNS
,  ||| S:881 E:883 ||| ,
no  ||| S:883 E:886 ||| DT
matter  ||| S:886 E:893 ||| NN
of  ||| S:893 E:896 ||| IN
the  ||| S:896 E:900 ||| DT
analyzed  ||| S:900 E:909 ||| JJ
parameters ||| S:909 E:919 ||| NNS
,  ||| S:919 E:921 ||| ,
excepting  ||| S:921 E:931 ||| JJ
intestinal  ||| S:931 E:942 ||| JJ
type  ||| S:942 E:947 ||| NN
carcinomas ||| S:947 E:957 ||| NN
,  ||| S:957 E:959 ||| ,
which  ||| S:959 E:965 ||| WDT
presented  ||| S:965 E:975 ||| VBD
significant  ||| S:975 E:987 ||| JJ
high  ||| S:987 E:992 ||| JJ
values  ||| S:992 E:999 ||| NNS
( ||| S:999 E:1000 ||| -LRB-
p=0.003 ||| S:1000 E:1007 ||| NNP
)  ||| S:1007 E:1009 ||| -RRB-
at  ||| S:1009 E:1012 ||| IN
the  ||| S:1012 E:1016 ||| DT
advancing  ||| S:1016 E:1026 ||| JJ
edge ||| S:1026 E:1030 ||| NN
.  ||| S:1030 E:1032 ||| .
VEGF  ||| S:1032 E:1037 ||| NNP
score  ||| S:1037 E:1043 ||| NN
revealed  ||| S:1043 E:1052 ||| VBD
significant  ||| S:1052 E:1064 ||| JJ
differences  ||| S:1064 E:1076 ||| NNS
related  ||| S:1076 E:1084 ||| VBN
to  ||| S:1084 E:1087 ||| TO
histological  ||| S:1087 E:1100 ||| VB
type  ||| S:1100 E:1105 ||| NN
( ||| S:1105 E:1106 ||| -LRB-
p=0.020 ||| S:1106 E:1113 ||| NNP
) ||| S:1113 E:1114 ||| -RRB-
,  ||| S:1114 E:1116 ||| ,
differentiation  ||| S:1116 E:1132 ||| JJ
degree  ||| S:1132 E:1139 ||| NN
of  ||| S:1139 E:1142 ||| IN
the  ||| S:1142 E:1146 ||| DT
intestinal  ||| S:1146 E:1157 ||| JJ
type  ||| S:1157 E:1162 ||| NN
carcinomas  ||| S:1162 E:1173 ||| NNS
( ||| S:1173 E:1174 ||| -LRB-
p=0.036 ||| S:1174 E:1181 ||| NNP
)  ||| S:1181 E:1183 ||| -RRB-
and  ||| S:1183 E:1187 ||| CC
depth  ||| S:1187 E:1193 ||| NN
of  ||| S:1193 E:1196 ||| IN
invasion  ||| S:1196 E:1205 ||| NN
( ||| S:1205 E:1206 ||| -LRB-
p=0.049 ||| S:1206 E:1213 ||| NNP
) ||| S:1213 E:1214 ||| -RRB-
.  ||| S:1214 E:1216 ||| .
In  ||| S:1216 E:1219 ||| IN
case  ||| S:1219 E:1224 ||| NN
of  ||| S:1224 E:1227 ||| IN
metastases ||| S:1227 E:1237 ||| NN
,  ||| S:1237 E:1239 ||| ,
the  ||| S:1239 E:1243 ||| DT
levels  ||| S:1243 E:1250 ||| NNS
of  ||| S:1250 E:1253 ||| IN
VEGF  ||| S:1253 E:1258 ||| NNP
expression  ||| S:1258 E:1269 ||| NN
were  ||| S:1269 E:1274 ||| VBD
higher  ||| S:1274 E:1281 ||| JJR
in  ||| S:1281 E:1284 ||| IN
the  ||| S:1284 E:1288 ||| DT
primary  ||| S:1288 E:1296 ||| JJ
tumor ||| S:1296 E:1301 ||| NN
,  ||| S:1301 E:1303 ||| ,
without  ||| S:1303 E:1311 ||| IN
statistically  ||| S:1311 E:1325 ||| JJ
significant  ||| S:1325 E:1337 ||| JJ
differences  ||| S:1337 E:1349 ||| NNS
( ||| S:1349 E:1350 ||| -LRB-
p ||| S:1350 E:1351 ||| CD
> ||| S:1351 E:1352 ||| CD
0.05 ||| S:1352 E:1356 ||| CD
) ||| S:1356 E:1357 ||| -RRB-
.  ||| S:1357 E:1359 ||| .
It  ||| S:1359 E:1362 ||| PRP
were  ||| S:1362 E:1367 ||| VBD
significant  ||| S:1367 E:1379 ||| JJ
differences  ||| S:1379 E:1391 ||| NNS
of  ||| S:1391 E:1394 ||| IN
intratumoral  ||| S:1394 E:1407 ||| JJ
VEGF  ||| S:1407 E:1412 ||| NNP
expression  ||| S:1412 E:1423 ||| NN
depending  ||| S:1423 E:1433 ||| VBG
on  ||| S:1433 E:1436 ||| IN
CD105+  ||| S:1436 E:1443 ||| NNP
MVD  ||| S:1443 E:1447 ||| NNP
values  ||| S:1447 E:1454 ||| NNS
( ||| S:1454 E:1455 ||| -LRB-
p=0.019 ||| S:1455 E:1462 ||| NNP
) ||| S:1462 E:1463 ||| -RRB-
,  ||| S:1463 E:1465 ||| ,
but  ||| S:1465 E:1469 ||| CC
not  ||| S:1469 E:1473 ||| RB
with  ||| S:1473 E:1478 ||| IN
α-SMA+  ||| S:1478 E:1485 ||| NNP
MVD  ||| S:1485 E:1489 ||| NNP
( ||| S:1489 E:1490 ||| -LRB-
p ||| S:1490 E:1491 ||| CD
> ||| S:1491 E:1492 ||| CD
0.05 ||| S:1492 E:1496 ||| CD
) ||| S:1496 E:1497 ||| -RRB-
.  ||| S:1497 E:1499 ||| .
Angiogenesis  ||| S:1499 E:1512 ||| RB
evaluated  ||| S:1512 E:1522 ||| VBN
through  ||| S:1522 E:1530 ||| IN
the  ||| S:1530 E:1534 ||| DT
VEGF  ||| S:1534 E:1539 ||| NNP
and  ||| S:1539 E:1543 ||| CC
MVD  ||| S:1543 E:1547 ||| NNP
( ||| S:1547 E:1548 ||| -LRB-
CD105+  ||| S:1548 E:1555 ||| NNP
and  ||| S:1555 E:1559 ||| CC
α-SMA+ ||| S:1559 E:1565 ||| CD
)  ||| S:1565 E:1567 ||| -RRB-
expression  ||| S:1567 E:1578 ||| NN
is  ||| S:1578 E:1581 ||| VBZ
correlated  ||| S:1581 E:1592 ||| VBN
with  ||| S:1592 E:1597 ||| IN
the  ||| S:1597 E:1601 ||| DT
progression  ||| S:1601 E:1613 ||| NN
and  ||| S:1613 E:1617 ||| CC
metastasis  ||| S:1617 E:1628 ||| NN
of  ||| S:1628 E:1631 ||| IN
gastric  ||| S:1631 E:1639 ||| JJ
cancer  ||| S:1639 E:1646 ||| NN
and  ||| S:1646 E:1650 ||| CC
could  ||| S:1650 E:1656 ||| MD
be  ||| S:1656 E:1659 ||| VB
considered  ||| S:1659 E:1670 ||| VBN
a  ||| S:1670 E:1672 ||| DT
prognostic  ||| S:1672 E:1683 ||| JJ
marker  ||| S:1683 E:1690 ||| NN
of  ||| S:1690 E:1693 ||| IN
these  ||| S:1693 E:1699 ||| DT
tumors ||| S:1699 E:1705 ||| NNS
.  ||| S:1705 E:1707 ||| .
